1-11 of 11
Tatsuya Yamashita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita, Hironori Koga, Tsutomu Masaki, Naoyoshi Yatsuzuka, Masato Suzuki, Satoshi Nagao, Shuichi Kaneko, Hiromitsu Kumada
Journal: Liver Cancer
Liver Cancer 1–13.
https://doi.org/10.1159/000542572
Published Online: 14 November 2024
View article titled, First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial
Open the PDF for First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial in another window
Journal Articles

Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2024) 13 (6): 671–673.
https://doi.org/10.1159/000539205
Published Online: 06 May 2024
View article titled, Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
Open the PDF for Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study” in another window
Journal Articles

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 401–412.
https://doi.org/10.1159/000535501
Published Online: 28 November 2023
View article titled, Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Open the PDF for Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study in another window
Journal Articles

Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

Subject Area:
Gastroenterology , Oncology
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, Masatoshi Kudo, Yoshitaka Inaba, Manabu Morimoto, Kaoru Tsuchiya, Satoshi Shimizu, Yasushi Kojima, Atsushi Hiraoka, Kazuhiro Nouso, Hiroshi Aikata, Kazushi Numata, Tosiya Sato, Takuji Okusaka, Junji Furuse
Journal: Liver Cancer
Liver Cancer (2024) 13 (2): 193–202.
https://doi.org/10.1159/000531820
Published Online: 07 July 2023
View article titled, Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Open the PDF for Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD in another window
Journal Articles

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo
Journal: Liver Cancer
Liver Cancer (2021) 10 (3): 275–284.
https://doi.org/10.1159/000515553
Published Online: 27 April 2021
View article titled, Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Open the PDF for Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial in another window
Journal Articles

Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Subject Area:
Gastroenterology , Oncology
Kazuomi Ueshima, Sadahisa Ogasawara, Masafumi Ikeda, Yutaka Yasui, Takeshi Terashima, Tatsuya Yamashita, Shuntaro Obi, Shinpei Sato, Hiroshi Aikata, Takumi Ohmura, Hidekatsu Kuroda, Takamasa Ohki, Kengo Nagashima, Yoshihiko Ooka, Masahiro Takita, Masayuki Kurosaki, Kazuaki Chayama, Shuichi Kaneko, Namiki Izumi, Naoya Kato, Masatoshi Kudo, Masao Omata
Journal: Liver Cancer
Liver Cancer (2020) 9 (5): 583–595.
https://doi.org/10.1159/000508724
Published Online: 24 July 2020
View article titled, Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma in another window
Journal Articles

Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver

Subject Area:
Gastroenterology , Oncology
Yoshiaki Shimizu, Kuniaki Arai, Taro Yamashita, Tatsuya Yamashita, Tetsuro Shimakami, Kazunori Kawaguchi, Kazuya Kitamura, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Azusa Kitao, Kazuto Kozaka, Satoshi Kobayashi, Shuichi Kaneko
Journal: Liver Cancer
Liver Cancer (2020) 9 (3): 261–274.
https://doi.org/10.1159/000504889
Published Online: 07 January 2020
View article titled, Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver
Open the PDF for Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver in another window
Journal Articles

Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan

Subject Area:
Gastroenterology , Oncology
Atsushi Hiraoka, Kojiro Michitaka, Takashi Kumada, Namiki Izumi, Masumi Kadoya, Norihiro Kokudo, Shoji Kubo, Yutaka Matsuyama, Osamu Nakashima, Michiie Sakamoto, Tadatoshi Takayama, Takashi Kokudo, Kosuke Kashiwabara, Susumu Eguchi, Tatsuya Yamashita, Masatoshi Kudo, The Liver Cancer Study Group of Japan
Journal: Liver Cancer
Liver Cancer (2019) 8 (5): 403–411.
https://doi.org/10.1159/000495944
Published Online: 18 February 2019
View article titled, Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
Open the PDF for Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan in another window
Journal Articles

Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Subject Area:
Gastroenterology , Oncology
Takeshi Terashima, Tatsuya Yamashita, Tadashi Toyama, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Journal: Liver Cancer
Liver Cancer (2019) 8 (2): 130–139.
https://doi.org/10.1159/000489505
Published Online: 14 June 2018
View article titled, Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open the PDF for Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in another window
Journal Articles

Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma

Subject Area:
Gastroenterology , Oncology
Takeshi Terashima, Tatsuya Yamashita, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Journal: Liver Cancer
Liver Cancer (2017) 6 (3): 236–249.
https://doi.org/10.1159/000472262
Published Online: 17 May 2017
View article titled, Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma
Open the PDF for Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma in another window
Journal Articles

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Osamu Matsui, Namiki Izumi, Hiroko Iijima, Masumi Kadoya, Yasuharu Imai, Takuji Okusaka, Shiro Miyayama, Kaoru Tsuchiya, Kazuomi Ueshima, Atsushi Hiraoka, Masafumi Ikeda, Sadahisa Ogasawara, Tatsuya Yamashita, Tetsuya Minami, Koichiro Yamakado, on behalf of the Liver Cancer Study Group of Japan
Journal: Liver Cancer
Liver Cancer (2014) 3 (3-4): 458–468.
https://doi.org/10.1159/000343875
Published Online: 13 October 2014
View article titled, JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Open the PDF for JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan in another window